MDMA vs Ketamine for PTSD

For Canadian patients with PTSD, the realistic 2026 psychedelic-assisted therapy decision often comes down to MDMA-AT versus ketamine therapy. Both have published evidence; both are accessed in Canada under different regulatory frameworks; the decision is shaped by access, coverage, evidence weighting, and clinical fit. MDMA-AT has the strongest published PTSD-specific RCT evidence in psychedelic medicine — Mitchell 2021 MAPP1 (d≈0.91) and Mitchell 2023 MAPP2 (d≈1.0) Phase 3 trials in Nature Medicine — but is SAP-only access in Canada and substantially more expensive (CAD $7,500–$15,000 per program). Ketamine has smaller PTSD effect sizes (Bryant 2024 pooled g≈0.20 bias-corrected) but broader Canadian access through off-label legal pathways, established VAC coverage for service-related TRD/chronic pain, WSIB Ontario formulary listings, and lower per-program cost (CAD $1,530–$6,930). Some patients sequence both — ketamine for acute crisis stabilization, MDMA-AT later for trauma processing in a more stable phase. This article walks through the honest decision framework.

Key takeaways

• MDMA-AT has stronger PTSD-specific RCT evidence: Mitchell 2021 MAPP1 (d≈0.91) and 2023 MAPP2 (d≈1.0) Phase 3 trials. Effect sizes substantially exceed ketamine PTSD pooled meta-analysis (Bryant 2024 g≈0.20 bias-corrected).
• Ketamine has broader Canadian access: off-label legal across Canada; established VAC coverage for service-related TRD/chronic pain; WSIB Ontario Psychotraumatic and Serious Injury formularies; WCB Alberta formal listing; lower cost per program.
• Cost asymmetry: MDMA-AT ~CAD $7,500–$15,000 per program (3 dosing sessions); ketamine ~CAD $1,530–$6,930 per program (4–8 dosing sessions). Ketamine is typically lower per program for most Canadian patients.
• Coverage asymmetry: MDMA-AT — VAC case-by-case for service-related PTSD; otherwise out-of-pocket. Ketamine — broader VAC, WSIB, WCB pathways; Spravato has private prior-auth coverage (but Spravato is TRD-only, not PTSD-approved).
• Session structure: MDMA-AT 3 dosing sessions over ~12 weeks (longer total program); ketamine 4–8 IV sessions over 2–3 weeks (acute course) plus maintenance.
• Mechanism: MDMA serotonin/NE/oxytocin (emotional warmth, "extended therapeutic window"); ketamine NMDA antagonism (rapid mood/dissociative).
• Many patients pursue both at different times — sequencing depends on clinical presentation, comorbidity, and access timeline.

Side-by-side comparison

The evidence-strength comparison — honest framing

MDMA-AT has substantially stronger PTSD-specific RCT evidence. This is not a marketing claim; it is the published reality:

• Mitchell 2021 MAPP1 Phase 3 (N=90) — d≈0.91 CAPS-5
• Mitchell 2023 MAPP2 Phase 3 (N=104) — d≈1.0 CAPS-5
• Mithoefer 2018 Phase 2 (N=26) in service-connected populations — sustained 12-month benefit
• ~67% of MDMA-AT participants no longer meeting PTSD criteria at study end (MAPP1)

The ketamine PTSD evidence is real but smaller in magnitude:

• Feder 2014 Phase 2 single-dose (N=41) — significant but transient effect
• Feder 2021 Phase 2 repeated-dose (N=30) — d≈1.13 in this trial, but sample is small
• Bryant 2024 meta-analysis (6 RCTs) — pooled g≈0.27 omnibus, declining to g≈0.20 after trim-and-fill bias correction; effects shrink against active midazolam controls

The honest framing: for the same condition (PTSD), MDMA-AT's published Phase 3 effect sizes are several times larger than ketamine's pooled meta-analytic effect sizes at this point in the evidence base. This is the strongest single argument for MDMA-AT in PTSD.

For the ketamine PTSD evidence detail, see Ketamine Therapy for PTSD. For the MDMA-AT for PTSD detail, see MDMA-Assisted Therapy for PTSD.

The access asymmetry — the practical counter-balance

Ketamine has dramatically broader Canadian access — and for many patients this is the deciding factor:

• Off-label legal pathway across Canada for ketamine. Provincial regulator standards apply (CPSA, CPSO OHPIP, CPSBC NHMSFAP, CPSS NHTF) but the legal architecture is open. No SAP required.
• Spravato Health Canada-approved for TRD since May 2020. While not approved for PTSD, the Spravato pathway provides a Health-Canada-approved entry point for patients with comorbid TRD + PTSD.
• Edmonton Misericordia/Grey Nuns publicly funded IV ketamine program (AHCIP-covered) for ultra-resistant TRD — accessible to comorbid PTSD patients.
• VAC coverage infrastructure for ketamine is established (~433 veterans averaging $10,109 in FY2024-25 per VAC briefing).
• WSIB Ontario formal listing for ketamine and esketamine on Psychotraumatic, Serious Injury, Chronic Pain Disability formularies with prior authorization.
• WCB Alberta formal pathway for ketamine.

By contrast, MDMA-AT in Canada is SAP-only with ~41 cumulative approvals through February 2024 (versus ~176 psilocybin and untold thousands of ketamine treatments). Approval rates declined further through 2025 per PsyCan reporting.

The honest framing: for many Canadian patients, the meaningful question is not "which has better evidence" but "which can I actually access within a realistic timeline and budget." Ketamine often wins this question even when MDMA-AT has stronger evidence.

The cost asymmetry

For most privately-insured Canadian patients with comorbid TRD, Spravato (with private prior authorization for TRD) is often the cheapest net out-of-pocket pathway, even though it is not PTSD-approved. The PTSD benefit is secondary to the depression treatment.

For service-connected veterans, both pathways may be accessible through VAC; ketamine has more streamlined coverage infrastructure but MDMA-AT case-by-case is real.

For uninsured private-pay patients, ketamine therapy is often substantially cheaper than MDMA-AT.

For the cost detail, see MDMA-Assisted Therapy Cost in Canada and Ketamine Therapy Cost in Canada.

The session-experience comparison

MDMA dosing day (~6–8 hours):

• Conversational availability during peak — patient and therapy team engaged in active trauma-focused work
• Emotional warmth, oxytocin-mediated relational opening
• Therapists conduct active therapeutic exchange during the "extended therapeutic window"
• 3 dosing sessions over ~12 weeks plus 3 preparation + 9 integration sessions

Ketamine dosing day (~90–120 min IV; ~150–180 min Spravato):

• Inward-focused dissociative experience during peak
• Therapists provide monitoring and grounding presence; less active engagement during peak intensity
• Faster acute response; rapid onset (1–5 min IV; 10–20 min Spravato)
• 4–8 IV sessions over 2–3 weeks (CANMAT 2021); or 12 Spravato sessions over 8 weeks
• Maintenance dosing typically required for sustained benefit

Patient preference matters: some patients prefer the MDMA-AT model where they remain conversationally engaged during dosing — particularly for trauma-processing work. Others prefer the more inward-focused ketamine experience. The ATMA CENA intake call discusses preference and clinical fit.

The decision framework — practical

Choose MDMA-AT if:

• PTSD is the primary indication without dominant comorbid TRD or chronic pain
• You have a willing SAP-trained prescribing physician and can navigate the 2–8 week SAP review timeline
• You have VAC coverage as a service-connected veteran, or
• You have substantial out-of-pocket capacity ($7,500–$15,000) if VAC denies coverage
• You value the strongest published RCT evidence and the "extended therapeutic window" model with active trauma-focused work during dosing
• You can commit to the 12-week three-session program without time pressure

Choose ketamine therapy if:

• You need access within weeks rather than months
• You have private insurance covering Spravato for documented comorbid TRD
• You have established VAC coverage for service-related conditions
• You have WSIB Ontario or WCB Alberta workers' compensation for compensable PTSD
• Cost is a meaningful constraint — ketamine programs are typically 30–60% cheaper than MDMA-AT
• You have comorbid TRD as a primary or significant indication (ketamine evidence is far stronger for TRD)
• You have comorbid chronic pain (MDMA-AT does not target pain mechanism; ketamine does)
• You prefer the shorter session model

Consider both at different times if:

• Acute crisis or rapid stabilization needed → ketamine first for fast acute response
• Trauma processing work is the long-term goal → MDMA-AT after stabilization, in a more stable phase
• Comorbid TRD + PTSD → ketamine for depression component first; MDMA-AT for trauma processing later
• Treatment-resistant complex PTSD → some patients benefit from sequenced courses across modalities

The ATMA CENA intake discusses sequencing where appropriate.

How ATMA CENA supports both pathways

ATMA CENA's clinical model adapts to both:

• Ketamine: ATMA CENA's corporate clinics in Edmonton and Calgary deliver KAT primarily through IM and SL ketamine; coordinated care arrangements support patients pursuing IV-led care or Spravato through external providers.
• MDMA-AT: ATMA CENA supports preparation and integration for SAP-pathway patients via coordinated care in coordination with the patient's prescribing physician. The medical SAP application is initiated by the prescribing physician.
• The intake call discusses both pathways honestly. For some PTSD patients, one pathway is clearly the right fit; for others, both are legitimate options or sequencing makes sense.

Frequently asked questions

Which is more effective for PTSD? On published RCT evidence, MDMA-AT has substantially larger effect sizes (d≈0.91-1.0 in Phase 3) versus ketamine PTSD pooled meta-analysis g≈0.20 bias-corrected. Both work; the magnitudes differ.

Which is more accessible in Canada? Ketamine. Off-label legal across Canada; established VAC, WSIB, WCB coverage pathways; Spravato Health-Canada-approved for TRD with private prior-auth coverage. MDMA-AT is SAP-only with limited access volume.

Which costs less? Ketamine, typically. MDMA-AT ~$7,500–$15,000 per program; ketamine ~$1,530–$6,930 per ATMA CENA KAT program. Spravato has private prior-auth coverage that often makes it the cheapest net out-of-pocket option for patients with comorbid TRD.

Which has better VAC coverage for veterans? Ketamine has more established VAC coverage infrastructure (~433 veterans, ~$10,109 average in FY2024-25). MDMA-AT is case-by-case for service-related PTSD where SAP-approved. Veterans with strong VAC PTSD documentation may access either; ketamine path is more streamlined operationally.

Can I do both? Yes — sequenced at different times. Many Canadian patients pursue ketamine for acute crisis stabilization or comorbid TRD, then consider MDMA-AT later for trauma processing in a more stable phase. The ATMA CENA intake discusses sequencing.

What if I have comorbid TRD plus PTSD? Common profile. Ketamine has substantially stronger TRD evidence (CANMAT 2021 third-line; ELEKT-D 2023 NEJM non-inferior to ECT). MDMA-AT has stronger PTSD evidence. Sequencing across modalities is one approach.

What if I have chronic pain plus PTSD? Ketamine has established chronic pain evidence (CRPS, refractory neuropathic pain) and ASRA 2018 consensus guidelines. MDMA-AT does not target pain mechanism. For comorbid PTSD + chronic pain, ketamine is typically the more comprehensive option.

What if I'm a first responder with workplace PTSD? Provincial workers' compensation pathways apply. WSIB Ontario covers ketamine on multiple specialty formularies; WCB Alberta has formal ketamine coverage. MDMA-AT case-by-case under presumptive PTSD legislation. Verify with your provincial workers' compensation board.

Will the FDA decision affect my Canadian access? The August 2024 FDA Complete Response Letter on Lykos's MDMA-AT for PTSD application does not change Canadian SAP-pathway operations. Canadian SAP access continues independently.

What's the longest-term durability evidence? For MDMA-AT, long-term follow-up of MAPS-supported Phase 2 trials demonstrated sustained PTSD reduction years after the three-session course. For ketamine, durability typically requires maintenance dosing; Phillips 2019 Royal Ottawa demonstrated sustained benefit with maintenance.

Where can I access each in Canada? MDMA-AT: TheraPsil-trained clinicians; MAPS Canada providers; Numinus-network; Quebec collective; ATMA CENA supports via coordinated care. Ketamine: SABI Mind, Toronto Ketamine Clinic, Ontario Ketamine and Infusion Centre, Braxia Health, Edmonton Misericordia/Grey Nuns public program, ATMA CENA corporate clinics (IM/SL), and many others across Canada.

Sources

1. ATMA CENA — coordinated care: https://psychedelic.healthcare/find-care
2. Mitchell JM, et al. (2021). MDMA-assisted therapy for severe PTSD: MAPP1 Phase 3. Nat Med. https://pubmed.ncbi.nlm.nih.gov/33972795/
3. Mitchell JM, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: MAPP2 Phase 3. Nat Med. https://pubmed.ncbi.nlm.nih.gov/37709999/
4. Mithoefer MC, et al. (2018). Phase 2 RCT in military veterans, firefighters, police. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
5. Feder A, et al. (2014). Single-dose IV ketamine for chronic PTSD. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/24740528/
6. Feder A, et al. (2021). Repeated ketamine for chronic PTSD. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/37404970/
7. Bryant J, et al. (2024). Meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol. https://pmc.ncbi.nlm.nih.gov/articles/PMC10791091/
8. Du R, et al. (2022). Multivariate meta-analysis of ketamine for PTSD. Front Psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC8959757/
9. Sicignano DJ, et al. (2024). Ketamine for PTSD systematic review. Ann Pharmacother. https://pubmed.ncbi.nlm.nih.gov/37776285/
10. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
11. Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
12. WSIB Ontario — Ketamine and Esketamine Formulary Decision: https://www.wsib.ca/en/drug-formulary-listing-decision-ketamine-and-esketamine
13. FDA Complete Response Letter on MDMA-AT (August 2024): https://www.psychiatrictimes.com/view/fda-releases-complete-response-letter-on-declining-mdma-assisted-therapy-for-ptsd

Related articles in this cluster

• MDMA-Assisted Therapy in Canada
• MDMA-Assisted Therapy for PTSD
• MDMA-Assisted Therapy for Veterans
• How to Access MDMA-Assisted Therapy in Canada (SAP)
• Ketamine Therapy for PTSD
• Ketamine Therapy in Canada
• Find care near you

Last updated: 2026-05-06